BioControl Medical Ltd. has terminated the INOVATE HF
trial of its CardioFit vagus nerve stimulator (VNS) for the treatment of heart failure after a pre-specified interim analysis showed...
BioControl Becomes Latest Company To Report Disappointing Outcomes With VNS Therapy For Heart Failure
BioControl Medical has terminated the INOVATE HF trial of its CardioFit vagus nerve stimulator (VNS) for the treatment of heart failure after a pre-specified interim analysis showed the trial had little chance of meeting its primary endpoint. Despite the disappointing results, some physicians remain optimistic about VNS for heart failure and researchers continue to analyze patient subgroups and secondary endpoints to identify potential patients who might benefit from VNS therapy.
More from Clinical Trials
• By
In this week's Digital Health Roundup, MedTech Insight's Shubham Singh explores how Ketryx's launch of validated AI agents could reshape compliance automation in medtech. Marion Webb highlights news from BCI makers Synchron, Axoft and Subsense. Elizabeth Orr discusses AI advances at the FDA.
• By
Guardant Health’s methylation-based blood test – Shield MCD – showed a specificity of 98.6% and sensitivity of 75% across eight cancer types in its clinical validation data presented at ASCO.
• By
Abbott received the US FDA nod for its Tendyne system, offering a minimally invasive alternative to replace the valves of patients with severe mitral valve disease who are at risk for open-heart surgery.
• By
Cardiosense has launched a nationwide clinical study, SEISMIC-HF II, to validate its non-invasive, AI-powered technology for monitoring heart failure. The data will be used to file for US regulatory clearance of the Cardiosense heart failure monitoring platform.
More from R&D
• By
J&J's EMEA head of digital solutions, Julia Fishman, talks about the major hurdles in scaling digital innovation, tips for clinical adoption and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.
• By
The KINCISE 2 Surgical Automated System aims to “reduce the physical burden on surgeons compared to manual impaction in primary and revision hip and revision knee replacement procedures,” said J&J MedTech.
• By
Allen Burton, Abbott’s medical director of neuromodulation told Medtech Insight that the delivery system was developed to make the procedure easier for physicians, especially those who perform the implantations infrequently.